One-year clinical outcomes of everolimus- versus sirolimus-eluting
stents in patients with acute myocardial infarction
- Author(s)
- Kang-Yin Chen; Seung-Woon Rha; Lin Wang; Yong-Jian Li; Guang-Ping Li; Cheol Ung Choi; Chang Gyu Park; Hong Seog Seo; Dong Joo Oh; Myung Ho Jeong; Young Keun Ahn; Taek Jong Hong; Young Jo Kim; Shung Chull Chae; Seung Ho Hur; In Whan Seong; Jei Keon Chae; Myeong Chan Cho; Jang Ho Bae; Dong Hoon Choi; Yang Soo Jang; In Ho Chae; Hyo Soo Kim; Chong Jin Kim; Jung Han Yoon; Tae Hoon Ahn; Wook Sung Chung; Ki Bae Seung; Seung Jung Park; other Korea Acute Myocardial Infarction Registry Investigators
- Keimyung Author(s)
- Hur, Seung Ho
- Department
- Dept. of Internal Medicine (내과학)
- Journal Title
- International Journal of Cardiology
- Issued Date
- 2014
- Volume
- 176
- Issue
- 3
- Abstract
- Background: In contrast to many studies comparing everolimus-eluting stent (EES) with paclitaxel-eluting stent
(PES), data directly comparing EES with sirolimus-eluting stent (SES) are limited, especially in patients with
acute myocardial infarction (AMI).
Methods: This study includes 2911 AMI patients treated with SES (n= 1264) or EES (n= 1701) in Korea Acute
Myocardial Infarction Registry (KAMIR). Propensity scorematching was applied to adjust for baseline imbalance
in clinical and angiographic characteristics, yielding a total of 2400 well-matched patients (1200 receiving SES
and 1200 receiving EES). One-year clinical outcomeswere compared between the two propensity scorematched
groups.
Results: Baseline clinical and angiographic characteristics were similar between the two propensity score
matched groups. One-year clinical outcomes of the propensity score matched cohort were comparable between
the EES versus the SES groups including the rates of cardiac death (4.8% vs. 4.8%, P= 1.000), recurrent myocardial
infarction (1.4% vs. 1.7%, P= 0.619), target lesion revascularization (1.4% vs. 1.6%, P= 0.737), target lesion
failure (7.0% vs. 7.3%, P= 0.752), and probable or definite stent thrombosis (0.5% vs. 0.9%, P= 0.224) except for a
trend toward lower incidence of target vessel revascularization (1.9% vs. 3.0%, P= 0.087) and a lower rate of total
major adverse cardiac events (9.3% vs. 11.9%, P = 0.034) in the EES group.
Conclusions: The present propensity scorematched analysis performed in a large-scale, prospective, multicenter
registry suggests that the second-generation drug-eluting stent EES has at least comparable or even better safety
and efficacy profiles as compared with SES in the setting of AMI.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.